Brokerages Set Rubius Therapeutics Inc (NASDAQ:RUBY) PT at $33.00

Rubius Therapeutics Inc (NASDAQ:RUBY) has been given a consensus rating of “Buy” by the seven analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $33.00.

RUBY has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Rubius Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 29th. Guggenheim initiated coverage on shares of Rubius Therapeutics in a research report on Thursday, May 30th. They set a “buy” rating and a $25.00 price objective for the company.

NASDAQ:RUBY opened at $14.60 on Friday. The firm has a market cap of $1.10 billion and a P/E ratio of -6.43. The firm’s 50 day moving average price is $15.02. The company has a debt-to-equity ratio of 0.13, a current ratio of 18.64 and a quick ratio of 18.64. Rubius Therapeutics has a fifty-two week low of $12.70 and a fifty-two week high of $33.01.

Rubius Therapeutics (NASDAQ:RUBY) last released its earnings results on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). As a group, research analysts expect that Rubius Therapeutics will post -1.8 EPS for the current fiscal year.

In related news, President Torben Straight Nissen sold 2,100 shares of Rubius Therapeutics stock in a transaction on Monday, April 8th. The shares were sold at an average price of $20.00, for a total value of $42,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Langer sold 7,500 shares of Rubius Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $17.57, for a total transaction of $131,775.00. The disclosure for this sale can be found here. In the last three months, insiders sold 69,953 shares of company stock valued at $1,095,248. 58.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund bought a new stake in shares of Rubius Therapeutics during the 4th quarter worth $116,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Rubius Therapeutics by 320.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock worth $116,000 after purchasing an additional 5,481 shares during the period. SG Americas Securities LLC bought a new stake in shares of Rubius Therapeutics during the 1st quarter worth $117,000. BNP Paribas Arbitrage SA raised its stake in shares of Rubius Therapeutics by 19,092.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,485 shares of the company’s stock worth $135,000 after purchasing an additional 7,446 shares during the period. Finally, LPL Financial LLC bought a new stake in shares of Rubius Therapeutics during the 4th quarter worth $162,000. 93.75% of the stock is owned by institutional investors and hedge funds.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Featured Article: Analyzing a company’s cash flow statement

Analyst Recommendations for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.